| Melanie R Davidson, MD | |
|
1021 Coolidge St, Suite 5, Greeneville, TN 37743-4672 | |
| (423) 278-1842 | |
| (423) 278-1844 |
| Full Name | Melanie R Davidson |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 24 Years |
| Location | 1021 Coolidge St, Greeneville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487610507 | NPI | - | NPPES |
| Q003719 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD37717 (Tennessee) | Primary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0101237859 (Virginia) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Health Sonora | Sonora, CA | Hospital |
| Mark Twain Medical Center | San andreas, CA | Hospital |
| Doctors Medical Center | Modesto, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sonora Community Hospital | 4284538505 | 117 |
News Archive
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).
The health implications of polluting the environment weigh increasingly on our public consciousness, and pharmaceutical wastes continue to be a main culprit. Now a Tel Aviv University researcher says that current testing for these dangerous contaminants isn't going far enough.
Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.
To develop improved cancer immunotherapies, it is essential to understand how cancers shut down the natural immune response to foreign antigens. This current study demonstrates how mice lacking the Siah2 gene, fail to develop BRAF-mutation carrying melanoma from the corresponding cells, completely rejecting them. This could help in boosting the anticancer effect of existing specific immune checkpoint inhibitors, such as anti-PD-1 drugs.
The Center for BrainHealth, part of The University of Texas at Dallas, recently hosted the annual Friends of BrainHealth Scientist Selection Luncheon at the Dallas Country Club, where the following five scientists were awarded funds for their independently designed research studies.
› Verified 9 days ago
| Entity Name | Sonora Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891732418 PECOS PAC ID: 4284538505 Enrollment ID: O20031119000910 |
News Archive
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).
The health implications of polluting the environment weigh increasingly on our public consciousness, and pharmaceutical wastes continue to be a main culprit. Now a Tel Aviv University researcher says that current testing for these dangerous contaminants isn't going far enough.
Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.
To develop improved cancer immunotherapies, it is essential to understand how cancers shut down the natural immune response to foreign antigens. This current study demonstrates how mice lacking the Siah2 gene, fail to develop BRAF-mutation carrying melanoma from the corresponding cells, completely rejecting them. This could help in boosting the anticancer effect of existing specific immune checkpoint inhibitors, such as anti-PD-1 drugs.
The Center for BrainHealth, part of The University of Texas at Dallas, recently hosted the annual Friends of BrainHealth Scientist Selection Luncheon at the Dallas Country Club, where the following five scientists were awarded funds for their independently designed research studies.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melanie R Davidson, MD 1021 Coolidge St, Suite 5, Greeneville, TN 37743-4672 Ph: (423) 278-1842 | Melanie R Davidson, MD 1021 Coolidge St, Suite 5, Greeneville, TN 37743-4672 Ph: (423) 278-1842 |
News Archive
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).
The health implications of polluting the environment weigh increasingly on our public consciousness, and pharmaceutical wastes continue to be a main culprit. Now a Tel Aviv University researcher says that current testing for these dangerous contaminants isn't going far enough.
Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.
To develop improved cancer immunotherapies, it is essential to understand how cancers shut down the natural immune response to foreign antigens. This current study demonstrates how mice lacking the Siah2 gene, fail to develop BRAF-mutation carrying melanoma from the corresponding cells, completely rejecting them. This could help in boosting the anticancer effect of existing specific immune checkpoint inhibitors, such as anti-PD-1 drugs.
The Center for BrainHealth, part of The University of Texas at Dallas, recently hosted the annual Friends of BrainHealth Scientist Selection Luncheon at the Dallas Country Club, where the following five scientists were awarded funds for their independently designed research studies.
› Verified 9 days ago
Robert W. Locklear, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 895 E Andrew Johnson Hwy, Greeneville, TN 37745 Phone: 423-639-3330 Fax: 423-639-3342 | |
Maynard W Austin, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1404 Tusculum Blvd, Laughlin Mob, Suite 3100, Greeneville, TN 37745 Phone: 423-638-4114 | |
Muhammad M. Akmal, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 401 Takoma Ave, Greeneville, TN 37743 Phone: 423-278-1743 Fax: 423-278-1930 | |
Dr. Hiren B Patel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1420 Tusculum Blvd, Greeneville, TN 37745 Phone: 423-783-6400 | |
Dr. Isioma Aninyei, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 401 Takoma Ave, Greeneville, TN 37743 Phone: 828-687-5616 Fax: 828-650-8076 | |
Kimi Hmar Zook, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 810 W Church St, Greeneville, TN 37745 Phone: 423-798-1749 Fax: 423-798-1755 | |
Thomas F Beckner Iii, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1404 Tusculum Blvd, Laughlin Mob, Suite 3100, Greeneville, TN 37745 Phone: 423-638-4114 |